多機(jī)制協(xié)同抗癌療法公布臨床試驗結(jié)果；創(chuàng)新減重組合療法獲積極進(jìn)展…… | 一周盤點

本期看點：

1. 抗體偶聯(lián)藥物（ADC）micvotabart pelidotin 用于治療復(fù)發(fā)/轉(zhuǎn)移性頭頸部鱗狀細(xì)胞癌（R/M HNSCC）的1期臨床 試驗結(jié)果積極， 與pembrolizumab聯(lián)合用于一線或二線及以上（1L/2L+）的患者時，客觀緩解率（ORR）達(dá)71%，疾病控制率（DCR）為100% 。

2. 線粒體 質(zhì)子載體TLC-6740聯(lián)用 GLP-1/GIP受體雙重激動劑tirzepatide治療肥胖，在一項早期臨床試驗中使受試者 24周平均減重13.3%，且 呈持續(xù)線性減重趨勢， 未導(dǎo)致瘦體重流失。

Micvotabart Pelidotin（MICVO）：公布1期臨床試驗數(shù)據(jù)

Pyxis Oncology公司宣布，其ADC療法micvotabart pelidotin（MICVO，原名PYX-201）用于治療復(fù)發(fā)/轉(zhuǎn)移性頭頸部鱗狀細(xì)胞癌的1期臨床試驗取得了積極的初步數(shù)據(jù)。MICVO以微管抑制劑（優(yōu)化的auristatin）作為有效載荷，能靶向腫瘤細(xì)胞外基質(zhì)（ECM）中的非細(xì)胞性結(jié)構(gòu)成分——纖連蛋白B結(jié)構(gòu)域（Extradomain-B Fibronectin，EDB+FN），通過直接殺傷癌細(xì)胞、降低細(xì)胞外基質(zhì)密度、抑制血管生成及激活抗腫瘤免疫，實現(xiàn)多機(jī)制協(xié)同抗癌。該藥已獲美國FDA授予的快速通道資格，用于鉑類和PD-（L）1抑制劑治療后疾病進(jìn)展的R/M HNSCC患者。

此次公布的結(jié)果顯示，MICVO單藥用于2L+ R/M HNSCC患者，確認(rèn)的ORR為46%，DCR為92%。MICVO與pembrolizumab聯(lián)合用于1L/2L+患者時，ORR提升至71%，DCR為100%。安全性方面，MICVO總體耐受良好，未觀察到4級ADC有效載荷治療相關(guān)不良事件，也沒有觀察到5級不良事件。

TLC-6740：公布1b/2a期聯(lián)合治療試驗數(shù)據(jù)

OrsoBio公司宣布，其新型口服、肝臟靶向的線粒體質(zhì)子載體TLC-6740在一項為期24周的1b/2a期臨床試驗中取得了積極的頂線數(shù)據(jù)。該研究評估了TLC-6740聯(lián)合GLP-1/GIP受體雙重激動劑tirzepatide治療肥胖的效果。TLC-6740是一種新型口服藥物，通過選擇性作用于肝臟線粒體，增加能量消耗，旨在促進(jìn)減重并改善代謝健康，包括改善胰島素敏感性和脂質(zhì)代謝。該藥正在開發(fā)用于肥胖、糖尿病和代謝功能障礙相關(guān)脂肪性肝炎（MASH）等疾病。

此次公布的結(jié)果顯示，在55名非糖尿病肥胖成人（平均BMI為37.5 kg/m2）中，聯(lián)合治療組（tirzepatide 5 mg+TLC-6740 180 mg）24周平均減重13.3%，較單用tirzepatide組患者（8.8%）額外多減重4.5%（約5.1公斤，相對提升51%，p=0.018）。此外，單藥組在24周時體重下降趨于平臺期，而聯(lián)合組仍呈持續(xù)線性減重趨勢。此外，TLC-6740聯(lián)合tirzepatide的治療顯著改善了患者的胰島素敏感性、肝臟健康和體成分，且未導(dǎo)致瘦體重流失。安全性方面，TLC-6740聯(lián)用tirzepatide的安全性和耐受性良好，胃腸道不良反應(yīng)與tirzepatide單藥治療相當(dāng)。

SAB-142：公布1期臨床試驗數(shù)據(jù)

SAB BIO公司公布了其在研人類抗胸腺細(xì)胞免疫球蛋白療法SAB-142的積極1期臨床試驗結(jié)果。SAB-142是一種人類多克隆免疫球蛋白，旨在治療自身免疫性1型糖尿病。該藥物可針對多種殺傷胰島β細(xì)胞的免疫細(xì)胞，調(diào)節(jié)它們的活性，從而起到保護(hù)胰島β細(xì)胞的作用。

此次公布的數(shù)據(jù)顯示，SAB-142耐受性良好，未引發(fā)血清病（0/68），且無任何抗藥抗體（ADA）相關(guān)不良事件（0/68），即使在再次給藥的健康受試者中亦如此，表明其免疫原性極低或無免疫原性。所有受試者均未發(fā)生藥物相關(guān)嚴(yán)重不良事件（SAE），大多數(shù)不良反應(yīng)為輕度、短暫的1級類流感癥狀及輸注部位反應(yīng)。藥效學(xué)方面，作為與靶點結(jié)合的標(biāo)志，SAB-142誘導(dǎo)了短暫性淋巴細(xì)胞減少（100%受試者），但1–3天內(nèi)即恢復(fù)至基線，恢復(fù)速度遠(yuǎn)快于其他免疫調(diào)節(jié)藥物，支持其在門診環(huán)境中的長期重復(fù)使用。

參考資料：

[1] Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor. Retrieved December 19, 2025, from https://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-from-us-phase-i-study-of-asc50-a-potential-best-in-class-oral-small-molecule-il-17-inhibitor-302641987.html

[2] Cullgen Reports Positive Results from Phase 1 Study of its Novel Non-Opioid Product Candidate CG001419 for Pain. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/12/3204662/0/en/Cullgen-Reports-Positive-Results-from-Phase-1-Study-of-its-Novel-Non-Opioid-Product-Candidate-CG001419-for-Pain.html

[3] Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/15/3205290/0/en/Abpro-Holdings-Announces-Submission-of-an-IND-Application-to-Initiate-a-Phase-1-Clinical-Trial-of-T-cell-engager-ABP-102-CT-P72-for-HER2-positive-Cancers.html

[4] Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/16/3206147/0/en/Recludix-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-REX-8756-an-Oral-STAT6-Inhibitor-to-Enter-into-the-Clinic.html

[5] Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint Antibody in Solid Tumors. Retrieved December 19, 2025, from https://www.pilatusbio.com/latest-news/pilatus-biosciences-announces-fda-clearance-of-ind-application-for-plt012-a-first-in-class-anti-cd36-metabolic-checkpoint-antibody-in-solid-tumors

[6] Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/17/3206978/0/en/Moleculin-Announces-Positive-Results-from-Phase-1-Clinical-Trial-Evaluating-WP1066-for-the-Treatment-of-Pediatric-Recurrent-Malignant-Brain-Tumors.html

[7] SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/17/3206921/0/en/SAB-BIO-Announces-Positive-Confirmatory-Clinical-Results-from-the-Phase-1-Study-of-SAB-142-in-Development-for-the-Treatment-of-Stage-3-T1D.html

[8] Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/17/3206848/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Study-of-NXP900-in-Combination-with-Osimertinib-in-Patients-with-NSCLC.html

[9] 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/17/3206872/0/en/4DMT-Announces-Positive-Interim-Clinical-Data-from-4D-710-AEROW-Phase-1-Clinical-Trial-in-Cystic-Fibrosis-Lung-Disease.html

[10] OrsoBio Announces Positive Topline Phase 1b/2a Clinical Data for its Oral Mitochondrial Protonophore TLC-6740 in Combination with Tirzepatide. Retrieved December 19, 2025, from https://orsobio.com/press-release/orsobio-announces-positive-topline-phase-1b-2a-clinical-data-for-its-oral-mitochondrial-protonophore-tlc-6740-in-combination-with-tirzepatide/#:~:text=Combination%20achieved%20an%20additional%204.5%25%20mean%20weight%20loss,with%20more%20than%20300%20patients%20dosed%20to%20date

[11] Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants. Retrieved December 19, 2025, from https://www.prnewswire.com/news-releases/thryv-therapeutics-announces-positive-phase-1-results-of-thrv-1268-in-obese-participants-302644754.html

[12] BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer. Retrieved December 19, 2025, from https://www.newsfilecorp.com/release/278219/BioVaxys-Announces-Positive-Phase-1-Clinical-Study-Results-with-MaveropepimutS-MVPS-in-Women-with-Hormone-Receptor-PositiveHER2-Negative-HRHER2-Stage-IIIII-Breast-Cancer?k=BioVaxys

[13] Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Na?ve Neovascular AMD. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/17/3207305/0/en/Kalaris-Therapeutics-Reports-Positive-Initial-Phase-1a-Data-for-TH103-in-Treatment-Na%C3%AFve-Neovascular-AMD.html

[14] ???, 'PARP/TNKS’ ?? ?? 1b/2? "IND ??". Retrieved December 19, 2025, from https://www.biospectator.com/news/view/27300

[15] Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/18/3207571/0/en/Sagimet-Biosciences-Announces-Positive-Results-from-the-Phase-1-PK-Clinical-Trial-of-Denifanstat-and-Resmetirom-Combination.html

[16] Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/18/3207556/0/en/Pyxis-Oncology-Announces-Positive-Preliminary-Phase-1-Data-for-Micvotabart-Pelidotin-MICVO-in-Recurrent-Metastatic-Head-and-Neck-Squamous-Cell-Carcinoma.html

[17] Peptinov Publishes Positive Phase 1 Results for PPV-06 in Nature Communications. Retrieved December 19, 2025, from https://www.prnewswire.com/news-releases/peptinov-publishes-positive-phase-1-results-for-ppv-06-in-nature-communications-302646257.html

[18] Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease. Retrieved December 19, 2025, from https://www.globenewswire.com/news-release/2025/12/18/3207568/0/en/Gain-Therapeutics-Announces-Positive-Results-in-Key-Exploratory-Endpoint-from-its-Phase-1b-Clinical-Study-of-GT-02287-in-People-with-Parkinson-s-Disease.html

免責(zé)聲明：本文僅作信息交流之目的，文中觀點不代 表藥 明康德立場，亦不代 表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導(dǎo)，請前往正規(guī)醫(yī)院就診。

版權(quán)說明：歡迎個人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機(jī)構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺。轉(zhuǎn)載授權(quán)請在「藥明康德」微信公眾號回復(fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。